The Fund Grade · free · no account needed
What grade does NYVTX get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
Davis New York Venture Fund A
#371 of 500 graded active funds · blend · large segment peer group
The point · specialist footprint
NYVTX sits mid pack for specialist backing among graded funds.
Bottom 20%
Bottom 40%
● Middle
Top 40%
Top 20%
The middle rungs sat between the extremes, and the pattern was monotonic: every step up in specialist backing came with better subsequent results. Not damning, not compelling. The fee decides whether it is worth it.
10,000+ funds tracked · the graded specialists among them drive every read
3 funds in the same segment carry an A. Members see the names and what they charge. See the alternatives →
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
NYVTX vs the Honor Roll · share card ↗Conviction exposure
25.5%
of the book in specialist-converged names
Late-stage weight
20%
of the book in Crowded or Fading names
Active share
94.8%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
Davis New York Venture Fund ranks 371 out of 500 graded funds, a D grade, with only 25.5% specialist backing. CVS at 4.2% and Tyson Foods at 3.1% are both Fading, meaning proven specialists are already leaving those trades. USB and VTRS show early conviction, but that is not enough to offset the broader weakness here.
→ Watch CVS, Tyson, and Cigna closely; specialists are exiting all three, which together make up roughly 10% of the fund.
→ Compare this D-grade fund against the three higher-graded peers in the same segment before holding further.
Support leaving these positions
Same family, higher grade
Read from today's disclosed book. Evidence, not advice.